JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Emergent BioSolutions Inc

Atvērts

SektorsVeselības aprūpe

8.58 -2.28

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.06

Max

8.79

Galvenie mērījumi

By Trading Economics

Ienākumi

99M

68M

Pārdošana

33M

222M

Peļņas marža

30.603

Darbinieki

900

EBITDA

120M

133M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+40.02% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

6M

323M

Iepriekšējā atvēršanas cena

10.86

Iepriekšējā slēgšanas cena

8.58

Ziņu noskaņojums

By Acuity

58%

42%

316 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Emergent BioSolutions Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. aug. 17:49 UTC

Galvenie tirgus virzītāji

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025. g. 11. aug. 17:18 UTC

Galvenie tirgus virzītāji

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025. g. 11. aug. 16:25 UTC

Peļņas

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025. g. 11. aug. 23:50 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025. g. 11. aug. 23:36 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025. g. 11. aug. 23:32 UTC

Tirgus saruna

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025. g. 11. aug. 23:02 UTC

Tirgus saruna

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025. g. 11. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement 2Q Rev $25.8M >EXOD

2025. g. 11. aug. 20:14 UTC

Tirgus saruna

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025. g. 11. aug. 19:12 UTC

Tirgus saruna

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025. g. 11. aug. 18:56 UTC

Tirgus saruna

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025. g. 11. aug. 18:31 UTC

Tirgus saruna

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025. g. 11. aug. 17:43 UTC

Tirgus saruna

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025. g. 11. aug. 17:28 UTC

Tirgus saruna

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025. g. 11. aug. 17:16 UTC

Tirgus saruna

Commodity Longs Fall to 11-Month Low -- Market Talk

2025. g. 11. aug. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025. g. 11. aug. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Says Sabadell Offer Remains in Effect

2025. g. 11. aug. 16:26 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Announced TSB Sale on July 1

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Salīdzinājums

Cenas izmaiņa

Emergent BioSolutions Inc Prognoze

Cenas mērķis

By TipRanks

40.02% augšup

Prognoze 12 mēnešiem

Vidējais 12 USD  40.02%

Augstākais 15 USD

Zemākais 9 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.95 / N/AAtbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

316 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.